GlucoTrack
GCTK | NASDAQ
$0.49
-$0.31 (-38.75%)
At close: Nov 2, 2026, 3:47 PM ET
GlucoTrack Company Profile
Company profile explainedCompany Profile
GlucoTrack, Inc. is a medical device company that focuses on the design, development, and commercialization of novel technologies for people with diabetes. The company is developing the GlucoTrack CBGM, a long-term implantable continuous blood glucose monitoring system for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.
Key Executives
| Name | Position |
|---|---|
| Erik C. Emerson | CEO & Director |
| Avner Gal MSc.EE | Co-Founder, Chairman Emeritus & Consultant |
| David Malka | Co-Founder |
| Drinda Benjamin | Chief Commercial Officer |
| Mark Tapsak | Chief Scientific Officer |
| Paul V. Goode | Chief Technical Officer & President |
| Vincent Wong | Chief Operations Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 8-K | Current Report |
| Oct 28, 2026 | 8-K | Current Report |
| Oct 22, 2026 | 8-K | Current Report |
| Oct 19, 2026 | 8-K | Current Report |
| Oct 13, 2026 | PRE 14A | Filing |
| Oct 14, 2026 | S-1/A | [Amend] Filing |
| Oct 13, 2026 | 425 | Filing |
| Oct 13, 2026 | 8-K/A | [Amend] Current Report |
| Sep 28, 2026 | 8-K | Current Report |
| Sep 24, 2026 | 424B5 | Filing |
GlucoTrack
| Country | United States |
| IPO Date | Apr 25, 2013 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Erik Emerson |
Contact Details
301 Route 17 North Rutherford,
New Jersey 07070 United States
Stock Details
| Ticker Symbol | GCTK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001506983 |
| CUSIP Number | 45824Q879 |
| ISIN Number | US45824Q8794 |
| SIC Code | 3841 |
Recent News
- 26 days ago / businesswire.comGlucotrack, Inc. Announces Reverse Stock Split
- 2 months ago / gurufocus.comGlucotrack, Inc. Announces Pricing of $3 Million Public Offering
- 2 months ago / benzinga.comWhy GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket
- 2 months ago / businesswire.comLōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities
- 2 months ago / gurufocus.comLōkahi Therapeutics™ Continues ai² Pipeline™ Division Collaboration with The University of Alabama to Advance Asset Evaluation and Biopharma Talent
- 2 months ago / gurufocus.comGlucotrack Announces $11.5 Million Financing
- 3 months ago / businesswire.comGlucotrack Achieves Key Compliance Milestone and Advances Strategic Transformation
Add to Watchlist
Select watchlists to add or remove GCTK